Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trialRussell E. Ware, Robert J. Adams, Barry R. Davis et al.|The Lancet|2015Cited by 518
TCD with Transfusions Changing to Hydroxyurea (TWiTCH): Hydroxyurea Therapy As an Alternative to Transfusions for Primary Stroke Prevention in Children with Sickle Cell AnemiaRussell E. Ware, Robert J. Adams, Barry R. Davis et al.|Blood|2015Cited by 17
Direct hemoglobin S polymerization inhibitor MCP435 completely halts ongoing disease pathophysiology in transgenic sickle cell disease miceAndrew N. Fleischman, Osheiza Abdulmalik, David R. Light et al.|Blood|2025Cited by 1
A Novel Direct Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease - <i>In Vivo</i> Efficacy of Ilx-002 in Humanized MiceOsheiza Abdulmalik, Andrew N. Fleischman, Veronica Bochenek et al.|Blood|2024Cited by 0